351 related articles for article (PubMed ID: 18477770)
1. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Porkka K; Koskenvesa P; Lundán T; Rimpiläinen J; Mustjoki S; Smykla R; Wild R; Luo R; Arnan M; Brethon B; Eccersley L; Hjorth-Hansen H; Höglund M; Klamova H; Knutsen H; Parikh S; Raffoux E; Gruber F; Brito-Babapulle F; Dombret H; Duarte RF; Elonen E; Paquette R; Zwaan CM; Lee FY
Blood; 2008 Aug; 112(4):1005-12. PubMed ID: 18477770
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
4. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Aplenc R; Blaney SM; Strauss LC; Balis FM; Shusterman S; Ingle AM; Agrawal S; Sun J; Wright JJ; Adamson PC
J Clin Oncol; 2011 Mar; 29(7):839-44. PubMed ID: 21263099
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.
Benjamini O; Dumlao TL; Kantarjian H; O'Brien S; Garcia-Manero G; Faderl S; Jorgensen J; Luthra R; Garris R; Thomas D; Kebriaei P; Champlin R; Jabbour E; Burger J; Cortes J; Ravandi F
Am J Hematol; 2014 Mar; 89(3):282-7. PubMed ID: 24779033
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M;
Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113
[TBL] [Abstract][Full Text] [Related]
12. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
[TBL] [Abstract][Full Text] [Related]
13. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Ottmann O; Dombret H; Martinelli G; Simonsson B; Guilhot F; Larson RA; Rege-Cambrin G; Radich J; Hochhaus A; Apanovitch AM; Gollerkeri A; Coutre S
Blood; 2007 Oct; 110(7):2309-15. PubMed ID: 17496201
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
Wong SF
J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib.
Shah NP
Drugs Today (Barc); 2007 Jan; 43(1):5-12. PubMed ID: 17315048
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib.
Lindauer M; Hochhaus A
Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
[TBL] [Abstract][Full Text] [Related]
19. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Bujassoum S; Rifkind J; Lipton JH
Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Jabbour E; Cortes J; Kantarjian H
Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
